PMID- 16321691
OWN - NLM
STAT- MEDLINE
DCOM- 20060316
LR  - 20131121
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 106
IP  - 2
DP  - 2006 Jan 13
TI  - Possible vascular role of increased plasma arginine vasopressin in congestive 
      heart failure.
PG  - 191-5
AB  - BACKGROUND: The present study was undertaken to determine the relation of cardiac 
      dysfunction with hormonal release in patients with congestive heart failure. 
      METHODS: Seventy-two patients with congestive heart failure were examined, who 
      were divided into four subgroups classified by the criteria of the New York Heart 
      Association (NYHA). Also, 10 age-matched subjects were served as a control. 
      Plasma arginine vasopressin (AVP), norepinephrine, atrial natriuretic peptide 
      (ANP) and brain natriuretic peptide (BNP) were determined. Cardiac index and 
      pulmonary capillary wedge pressure (PCWP) were measured in 51 of 72 patients. 
      RESULTS: Plasma AVP levels were significantly increased according to the severity 
      of NYHA classes; control: 1.7 +/- 0.2; NYHA I: 4.9 +/- 0.8, NYHA II: 5.5 +/- 0.9, 
      NYHA III: 13.4 +/- 2.6 (p < 0.05), NYHA IV: 26.9 +/- 5.6 pmol/l (p < 0.001). 
      Similar results were obtained with plasma norepinephrine, ANP and BNP. Plasma AVP 
      levels had negative correlation with cardiac index (r = -0.36, p < 0.01), but did 
      not with PCWP and plasma osmolality. Plasma BNP levels positively correlated with 
      PCWP (r = 0.44, p < 0.001), but did not with cardiac index. There was no 
      correlation between plasma AVP and BNP. Intensive therapy profoundly reduced all 
      the hormones according to the improvement of cardiac index in the patients with 
      NYHA class III and IV. The percent decrease in plasma AVP was 60.0%, a value 
      greater than that in plasma BNP. CONCLUSION: The present study indicates that 
      increased AVP may deteriorate cardiac function through V(1a) as well as V(2) 
      action, and that plasma AVP level is also a proper marker for the presence and 
      severity of congestive heart failure.
FAU - Nakamura, Tomohiro
AU  - Nakamura T
AD  - Department of Medicine, Jichi Medical School, Omiya Medical Center, Omiya-ku 
      Saitama, Saitama, Japan.
FAU - Funayama, Hiroshi
AU  - Funayama H
FAU - Yoshimura, Akio
AU  - Yoshimura A
FAU - Tsuruya, Yoshio
AU  - Tsuruya Y
FAU - Saito, Muneyasu
AU  - Saito M
FAU - Kawakami, Masanobu
AU  - Kawakami M
FAU - Ishikawa, San-e
AU  - Ishikawa SE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arginine Vasopressin/*blood
MH  - Atrial Natriuretic Factor/blood
MH  - Case-Control Studies
MH  - Female
MH  - Heart Failure/*blood
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Norepinephrine/blood
EDAT- 2005/12/03 09:00
MHDA- 2006/03/17 09:00
CRDT- 2005/12/03 09:00
PHST- 2004/09/10 00:00 [received]
PHST- 2005/01/19 00:00 [revised]
PHST- 2005/01/28 00:00 [accepted]
PHST- 2005/12/03 09:00 [pubmed]
PHST- 2006/03/17 09:00 [medline]
PHST- 2005/12/03 09:00 [entrez]
AID - S0167-5273(05)00403-1 [pii]
AID - 10.1016/j.ijcard.2005.01.043 [doi]
PST - ppublish
SO  - Int J Cardiol. 2006 Jan 13;106(2):191-5. doi: 10.1016/j.ijcard.2005.01.043.